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Summary
The epidermal growth factor system is a well characterized growth factor receptor pathway, the deregulation of
which has been be associated with neoplastic growth. Overexpression or amplification of the epidermal growth
factor receptor (EGFR) or one of its ligands has been linked with the malignant transformation of cells and is
correlated with poor prognosis in patients. PD 153035, a quinazoline, has been shown to inhibit the tyrosine kinase
activity of EGFR by blocking ATP binding (Fry et al., Science 265: 1093–1095, 1994). We set out to determine
whether the growth inhibition caused by this agent and five related compounds is a direct result of the blocking
of EGFR signaling. The effects on cell proliferation produced by these agents were tested on several tumor cell
lines and EC50 values obtained. The EGF responsive cell lines A-431 and MDA-MB-468 exhibit EC50 values
of 3 and 6.7 µM, respectively, for PD 153035 which was found to be the most potent. The agents were then
tested for their ability to block the paradoxical high dose EGF induced inhibition of A-431 and MDA-MB-468
cell growth as well as EGF induced phosphorylation in A-431 cells. These compounds are able to completely
block the effects of exogenously added EGF at 0.5 µM or less. However, higher doses (EC50’s ≥ 2 µM) were
needed to block the growth of human tumor cell lines potentially implicating a second site of action for these
compounds.
Introduction
The epidermal growth factor receptor (EGFR) is a
170 kDa transmembrane protein which exhibits in-
trinsic tyrosine kinase activity following binding to
one of its cognate ligands. Activation of EGFR leads
to many cellular responses including mitogenesis and
cellular proliferation [1]. Overexpression and/or am-
plification of EGFR has been found in many human
tumors including, gastric, esophageal, breast, prostate,
glioblastoma and lung, and has been associated with
poor prognosis [2–6]. Co-expression of EGFR and one
its ligands in tumor cells can enable growth to occur in
an autocrine or paracrine fashion [7]. These character-
istics make EFGR an attractive target for anti-cancer
therapies.
Therapeutic approaches against this target have
included immunotoxins, antibodies and small mol-
ecule inhibitors. The recombinant immunotoxin
DAB389EGF which consist of a truncated diphtheria
toxin fused to EGF has shown promise in preclinical
studies [1, 8]. Others have fused EGFR ligands with
RNase [9] or pseudomonas exotoxin [10]. Another
approach is to block the signal transduction pathway.
This has been attempted with monoclonal antibod-
ies directed to the extracellular domain of EGFR to
prevent the binding of ligands to the receptor. These
monoclonals have been shown to block the growth of
human tumor cells in vitro and in vivo and promising
results from clinical trails have been reported [11–14].
These strategies whilst hopeful are not without prob-
lems. Large molecules directed to EGFR such as the
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Figure 1. Chemical structures of the EGFR tyrosine kinase inhibitors tested.
immunotoxins and blocking antibodies are costly to
produce, are susceptible to proteolytic degradation,
can elicit an immune response and show poor pen-
etrance into solid tumors [4, 15]. As a result many
groups have been developing small molecule com-
pounds that block the EGFR signal transduction path-
way [14, 16]. These agents can be made more easily
and may show increased penetration into solid tu-
mors. Such compounds can be designed to compete
for ligand binding, a critical step in EGFR activa-
tion, or compete with EGFR–ATP binding, another
critical step in EGFR kinase activation. Compounds
which block the tyrosine kinase activity of the EGFR
by binding the intracellular portion of the receptor
may have an advantage over targeting the extracellu-
lar region especially in cases where truncation of the
extracellular domain of EGFR has led to ligand in-
dependent tyrosine kinase activity [17] or where high
levels of the shed extracellular domain are present in
the serum .
PD 153035 blocks the phosphorylation of tyrosine
residues by competing for the ATP binding site [18].
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Table 1. EC50 values (µM) for compounds screened on human tumor cell lines. Cell number quantitated
using crystal violet staining assay as described in Materials and methods then plotted as percentage
control. EC50 values were determined from resulting dose response curves
Cell line PD 153035 PD 157655 PD 158780 PD 159119 PD 159121 PD 158294
A-431 3 >50 32 40 >50 >50
MDA-468 6.7 >50 29 12 30 >50
MDA-231 25 >50 >50 >50 >50 >50
SKOV-3 2 1 18 >50 6.5 20
U-87 6 >50 >50 >50 >50 >50
We set out to determine if the anti-proliferative effects
of this and the related compounds shown in Figure 1
are the result of blocking the EGFR signal transduc-
tion pathway. This was examined by: (1) testing for
anti-proliferative effects, (2) testing for receptor spec-
ificity and (3) comparing the concentrations needed to
block exogenous EGF effects to those needed to block
proliferation.
Materials and methods
Cell lines and culture conditions
A-431, MDA-MB-468, U-87, SKOV-3 and MDA-
MB-231 cells were purchased from American Type
Culture Collection (Rockville, MD) and maintained
at 37◦C in a 5% CO2 atmosphere in minimal es-
sential medium (IMEM) (Gibco BRL, Grand Island,
NY) supplemented with 10% fetal bovine serum
(FBS) (Gibco BRL, Grand Island, NY). EGFR
transfectants and 32D cells were kindly provided
by Jacklyn M. Pierce and maintained at 37◦C in
5% CO2 atmosphere in RPMI 1640 (Mediatech,
Herndon, VA) supplemented with IL-3 (R&D
Systems, Minneapolis, MN) or EGF (UBI, Lake
Placid, NY) and 10% fetal bovine serum (Biofluids
Inc., Rockville, MD).
Crystal violet growth assay
Human tumor cell lines were plated in 96-well plate
(Falcon, Lincoln Park, NJ) at 1000–2000 cells per well
in IMEM media supplemented with 10% FBS. The
next day, 10 mM stock concentrations of drugs were
prepared by dissolving in DMSO then added to cells
after diluting in IMEM plus 10% FBS to the indicated
concentrations. Control cells were treated with the
corresponding concentrations of DMSO. After 3 days
Figure 2. Growth inhibitory effects on A-431 cells. Cells treated
with indicated concentrations of compounds. Cell number quan-
titated using crystal violet staining assay as described in Materials
and methods and plotted as percentage control. Results represent
mean ± standard deviation of three replicates per point.
Figure 3. Western blot of A-431 cells treated with PD 153035, PD
157655 and EGF. Whole cell lysates normalized to cell number
were probed with anti-phosphotyrosine as described in Materials
and methods.
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Figure 4. Blocking of EGF toxicity on A-431 cells with indicated concentrations of compounds. Cell number measured with Alamar blue assay
as described in Materials and methods and plotted as absorbance (570–600 nm). Results represent mean ± standard deviation of three replicates
per point.
the cells were gently washed with 1XPBS, fixed and
stained in a 25% methanol solution with 0.5% crystal
violet for 5 min. Excess stain was removed by gently
washing the plates in water. After plates were allowed
to dry overnight, the crystal violet was re-solubilized
with 0.1 M sodium citrate in 50% ethanol and absor-
bance read at 570 nm against a reference wavelength
of 405 nm.
Alamar blue growth assay
EGFR transfected 32D cells were plated in 96-well
plates (Falcon, Lincoln Park, NJ) at 2000 cells per
well in the presence if IL-3 or EGF. Immediately after
plating cells were treated with indicated concentra-
tions of compounds diluted from stock in RPMI 1640
supplemented 10% FBS plus IL-3 or EGF. Human
tumor cell lines were plated at 1000–2000 cells per
well and were allowed to attach overnight. The next
day, the cells were treated with compounds diluted in
IMEM plus 10% FBS to the indicated concentrations.
In each experiment control cells were treated with the
corresponding concentrations of DMSO. Twenty four
hours after the start of treatment, Alamar Blue Dye
(BioSource International, Camarillo, CA) was added
to the wells at a final concentration of 7.5% and 24 h
later absorbance measured at 570 and 600 nm and per-
Figure 5. Growth inhibitory effects of EGF on A-431 cells is
blocked bi-phasically by tyrosine kinase inhibitors. Cells treated
with 0.5 nM EGF were co-treated with indicated concentrations of
compounds. Cell number quantitated using crystal violet staining
assay as described in Materials and methods then plotted as percent-
age control. Results represent mean ± standard deviation of three
replicates per point.
centage control was calculated as [(O.D. 570 nm–O.D.
600 nm) of treated cells/(O.D. 570 nm–O.D. 600 nm)
of control cells] × 100%.
In vitro actions of EGFR tyrosine kinase inhibitors 103
Figure 6. Growth inhibitory effects of compounds cannot be reversed with indicated concentrations of EGF. Cell number measured with
crystal violet assay as described in Materials and methods and plotted as percentage control. Results represent mean ± standard deviation of
three replicates per point.
Western blotting
Human tumor cell lines were plated in 24-well plates
(Falcon, Lincoln Park, NJ) at 2 × 105 cells per well
in IMEM media supplemented with 10% FBS. The
next day, the media was replaced with IMEM plus
10% FBS supplemented with 50 ng/ml EGF alone
and in combination with each compound at 0.5 µM.
Control cells were treated with the corresponding con-
centrations of DMSO. After 2 or 8 h the cells were
washed twice with ice-cold 1× PBS (Biofluids Inc.,
Rockville, MD) and lysed 1 ml lysis buffer (50 mM
Tris–HCL, pH 7.4, 150 mM NaCl, 5 mM MgCL2,
1% Triton X-100, 5 mM EDTA, 5 mM EGTA, 1 mM
PMSF, 50 µg/ml approtinin, 50 ug/ml leupeptin and
2 mM sodium orthovanadate). Protein concentration
was determined by BCA method (Pierce, Rockford,
IL) according to manufacturer’s instructions. Thirty
micrograms of protein was electrophoresed under de-
naturing conditions on a Tris–glycine 16% acrylamide
gel (NOVEX Corp., San Diego, CA) and electroblot-
ted onto nitrocellulose membranes. Membranes were
blocked overnight in 5% BSA in 1XPBS. On the
next day membranes were incubated in primary anti-
body against anti-phosphotyrosine (UBI, Lake Placid,
NY) and visualized with ECL (Amersham, Arlington
Heights, IL).
Results
Initially we wanted to test the compounds (chemical
structures shown in Figure 1) for their growth inhib-
itory effects on a variety of human tumor cell lines.
Dose response curves were generated for each com-
pound for each cell line and the number of cells de-
termined using the crystal violet growth assay. EC50’s
were calculated from the each dose response curve
and are shown in Table 1. PD 153035 proved the
most potent on the cell lines tested with an EC50
of 3 µM for the epidermoid cell line A-431. The
five related compounds blocked growth to a lesser
extent as can be seen in Figure 2. Similar effects
were seen on the breast cancer cell line MDA-MB-
468 with an EC50 value of 6.7 µM for PD 153035.
Another breast cancer cell line MDA-MB-231 which
has a mutated K-Ras and does not respond to EGF
[19] had an EC50 of 25 µM. The ovarian carcinoma
cell line SKOV-3 which expresses high levels of the
EGFR family member erbB2 [20] but relatively low
levels of EGFR was the most sensitive to the com-
pounds with an EC50 for PD 153035 of 2 µM. Ad-
ditionally, U-87 cells which have low levels of EGFR
[21] have an EC50 similar to that of MDA-MB-468
cells.
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Figure 7. Dose response of EGFR transfected 32D cells grown in IL-3 or EGF. Cell number measured with Alamar blue assay as described in
Materials and methods and plotted as percentage control. Results represent mean ± standard deviation of three replicates per point.
Next we wanted to determine if the growth inhib-
itory effects seen with the compounds were due to
blocking the EGF signaling pathway. We used western
blot analysis to determine if the compounds could
block the EGF induced tyrosine kinase activity of A-
431 cells. Cells were incubated with 50 ng/ml EGF
and each compound at 0.5 µM for 2 or 8 h. Represen-
tative results with PD 153035 and 157655 can be seen
in Figure 3. As shown, each compound at 0.5 µM was
able to completely block the phosphorylation induced
by EGF. To further demonstrate specificity we used
another system to see if PD 153035 could block the
growth inhibitory effects of EGF. A-431 cells express
1–3 × 106 EGFR per cell and respond bi-phasically
to EGF [22]. This is a paradoxical effect of EGF
seen in vitro whereby low concentrations exhibit a
slight stimulation while higher concentrations cause
complete growth inhibition with an EC50 value of ap-
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proximately 0.5 nM. Using the results from the growth
inhibition assays we chose sublethal doses of the com-
pounds to block the effects of EGF in this system. A
fixed amount of each compound was incubated with
cells grown in increasing concentrations of EGF. As
seen in Figure 4 each compound was able to com-
pletely block the effects of EGF on A-431 cells at
concentrations ≤1 µM. A parallel set of experiments
were then conducted on MDA-MB-468 cells which
show similar EGFR expression and EGFR responsive-
ness to A-431 cells [23]. Results similar to A-431 were
obtained (data not shown). Next, we determined the
least amount of compound needed to block the EGF
effects on A-431 cells by incubating cells with an in-
hibitory concentration of EGF and decreasing amounts
of each compound. PD 153035 at 0.01 µM was able
to block the effects of EGF as shown in Figure 5. We
then tried to reverse the growth inhibitory effects of
the compounds seen at higher doses (10 µM) with the
addition of EGF. As seen in Figure 6, EGF was unable
to reverse the growth inhibitory effects of any of the
compounds.
To further test potency and specificity we screened
the compounds for growth inhibition in the 32D cell
system. 32D cells are an immortalized murine hema-
topoietic cell line that is dependent on IL-3 for growth.
However, when stably transfected with EGFR, they
are able to proliferate in response to EGF in the ab-
sence of IL-3 [24]. To quantitate cell number we
used the Alamar blue assay because these cells grow
in suspension and therefore, the crystal violet stain-
ing method was not suitable. The EGFR transfectants
were grown in the presence of EGF or IL-3 and
increasing concentration of the compounds. The re-
sulting dose response curves can be seen in Figure 7.
PD 153035 showed the most dramatic difference in
effect with EC50 values of 0.25 µM and 20 µM for
cells grown in EGF and IL-3, respectively. In addi-
tion, the compounds were tested for growth inhibition
on the parent 32D cell line grown in IL-3 and the re-
sulting dose responses were the same as those for the
transfectants in IL-3 (data not shown).
Discussion
In this study we wished to determine if the growth in-
hibitory effects of six small molecules on tumor cells
were due to blocking of the EGFR signaling pathway.
PD 153035 has been shown to block phosphoryla-
tion of tyrosine residues on EGFR by blocking the
ATP binding site on the cytoplasmic domain of the
receptor with an apparent Ki of 5.2 ± 1.2 pM [18]. We
tested the compounds for their growth inhibitory ef-
fects on a panel of EGFR expressing cell lines in vitro
and for their ability to block EGF induced tyrosine
kinase activity and EGF induced killing of tumor cells.
We then compared the concentrations needed for each
effect.
The compounds were first tested for their ability to
inhibit the growth of several tumor cell lines that vary
in their responsiveness to EGF. These in vitro exper-
iments generated EC50 values of 3 µM or greater for
cells which express high levels of EGFR and respond
to EGF. Further studies showed that these compounds
completely block the effects of exogenously added
EGF on these cells at levels less than 0.5 µM. These
results were shown by the ability to block the growth
inhibitory effects of EGF on A-431 cells and MDA-
MB-468 cells and by probing western blots of whole
cell extracts of EGF treated A-431 cells with anti-
phosphotyrosine. PD 153035 was able to block the
growth inhibitory effects of EGF on A-431 at a con-
centration as low as 0.01 µM. Additional experiments
using the novel 32D cell system were able to generate
dose response curves for cells grown in EGF and IL-3.
These experiments show that sustained repression of
EGFR tyrosine kinase activity can be achieved at low
concentrations of these compounds while higher levels
are required to block proliferation of what is appar-
ently non-EGF dependent growth. All of these studies
show that these lipophilic compounds were able to
penetrate the cell membrane and reach their proposed
site of action. In addition, exogenously added EGF
was unable to block the growth inhibition seen at
the higher drug concentrations. The culture condi-
tions for the growth experiments were the same as that
for the blocking experiments and preparation of cells
for western blots to eliminate variations do to serum
content.
Our results show that micromolar concentrations
were needed to block growth of human tumor cell lines
while nanomolar concentrations were able to com-
pletely block the effects of exogenously added EGF as
determined by the blocking experiments and western
blots analysis. In addition, blocking EGF dependent
growth in EGFR transfected 32D cells was achieved
in the nanomolar range, nearly two logs lower than
concentrations needed to block IL-3 dependent growth
in the same cells. This difference in response was not
seen in the tumor cell lines when we compared the
high EGFR expressing/EGF responsive cell lines to
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the low EGFR expressing/EGF non-responsive cells.
The EGF responsive A-431 and MDA-MB-468 cells
were less than 10-fold more sensitive to these com-
pounds than the EGF non-responsive MDA-MB-231
cells. Furthermore, SKOV-3 cells which have low
levels of EGFR and very high levels of the EGFR fam-
ily member erbB2 were actually the most sensitive.
This may reflect the smaller number of EGF receptors
which must be targeted in SKOV-3 cells and EGFR
transfected 32D cells.
Our experiments have shown that these compounds
can block the effects of EGF and can inhibit the growth
of tumor cells in vitro, however, concentrations needed
for growth inhibition are higher than those needed
to block the effects of exogenous EGF indicating a
second site of action for these compounds. A pos-
sible explanation for these results is the presence of
other EGFR family members in these cell lines. EGFR
can heterodimerize with at least two of these fam-
ily members [25]. These compounds do not block
EGF binding to its receptor, which is a prerequisite
for dimerization, therefore the mitogenic signal may
be propagated when EGFR heterodimerize with other
family members. In addition, PD 153035 was shown
to inhibit the tyrosine kinase activity of erbB-2 with
an IC50 of 2.3 µM [16] and its activity on the other
EGFR family members has not been looked at. These
compounds are growth inhibitory at levels greater than
1 µM which may be the levels needed to block the
other EGFR family members. This may also explain
the effects seen on SKOV-3 cells. Clearly inhibition
of other unrecognized ligand mediated or intracellular
tyrosine kinases is possible. This hypothesis is consis-
tent with results from Davies et al. [26] who showed
that the many protein kinases exhibited activity on
genes other than the desired target.
Bos et al. have shown that PD 153035 inhibits the
growth of several tumor cell lines in vitro and this cor-
relates with the level of EGF receptor expression [27].
In our studies we do not see this correlation. This may
be caused by the differences in growth conditions. Our
growth assays were conducted in media containing
10% FBS where as Bos et al. tested in reduced FBS
(0.5%). Our growth conditions may make the cells
less dependent on autocrine signaling and therefore
growth inhibition is seen only at concentrations that
are nonspecific.
We have shown that PD 153035 is the most effic-
acious of the compounds tested. In addition, we have
shown that these compounds can block the effects of
exogenous EGF at nanomolar concentrations and can
inhibit growth only at much higher concentrations.
Therefore, we conclude that the growth inhibitory ef-
fects are mediated by a second site of action for these
compounds.
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